CARDINAL HEALTH INC: directors' dealings · United States · SEC (Form 4)

About CARDINAL HEALTH INC

Cardinal Health Inc. is a major U.S. healthcare services and products company listed on the NYSE under ticker CAH, and headquartered in Dublin, Ohio, United States. Founded in 1971, the company has evolved into one of the most important players in the American healthcare supply chain, with a long-standing franchise in pharmaceutical distribution and a broader platform serving hospitals, pharmacies, physician offices, laboratories, ambulatory surgery centers, and patients at home. Cardinal Health reports two main operating segments. Pharmaceutical and Specialty Solutions is its largest and most strategically important business, centered on the distribution of branded, generic, and specialty pharmaceuticals, along with supporting services for manufacturers and healthcare providers. Global Medical Products and Distribution (GMPD) covers medical products, hospital supplies, and distribution solutions. In addition, the company groups several growth-oriented businesses under “Other,” including Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight Logistics. This portfolio mix shows a deliberate attempt to complement the low-margin but high-scale distribution core with higher-growth, higher-value healthcare services. From a competitive standpoint, Cardinal Health is one of the key U.S. pharmaceutical distributors, operating in an industry characterized by scale, logistics intensity, and tight margins. Its competitive advantages include national reach, purchasing and fulfillment capabilities, deep customer relationships, and the ability to provide integrated solutions across the healthcare value chain. The company also benefits from exposure to specialty pharmacy, patient support, home delivery, nuclear pharmacy operations, and data/performance solutions, which can support long-term earnings diversification. Recent developments have been strategically meaningful. In 2025, Cardinal Health announced and then completed the acquisition of Solaris Health, a leading urology MSO, strengthening The Specialty Alliance and expanding its multi-specialty management-services platform. It also completed the acquisition of Advanced Diabetes Supply Group, reinforcing its at-Home Solutions franchise. More recently, management raised its fiscal 2026 outlook and highlighted continued momentum across all five operating segments, alongside ongoing investments in automation, distribution capacity, and network optimization. For international investors, CAH remains a mature but actively transforming U.S. healthcare name, with a balance of defensive distribution exposure and selective growth optionality in specialty and home-based care.